arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

AGENUS INC

AGEN
$6.95 ▼ -0.54 (-7.28%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
47
Health
Weak
Neutral
auto_awesome

Analytical Summary

AGENUS INC demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $263.7M
Dividend Yield
Revenue Growth 40.2%
Op. Margin 44.6%
ROIC -6.2%
FCF / Share $-0.95
Trailing P/E 6.8x
Price / Book
FCF Yield
Debt / Equity -0.14
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$33.74M
↑ +40.2%
Net Income Profit after all expenses
$39.21M
↑ +248.7%
Operating Margin Operating profit as % of sales
44.6%
↑ +6.0% 11th
FCF / Share Free cash flow per share
$-0.95
↑ +9.5%
Long-Term Debt Long-term obligations
$30.19M
↓ -32.4%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
14
Returns
46
Financial Health
63
Cash Quality
99

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters